Share
It very much seems like bad news. I pose myself the following questions:
1) They only got made aware, one would think of there was a lack of evidence or material behind the inclusions that this would have been telegraphed
2) was this telegraphed by Novartis and as a result the company has kicked off a swathe of new studies. If so we’re Novartis not satisfied that suitable evidence would be provided in an appropriate time
3) is the product a dud - one would think not the case here because other jurisdictions are signing on (like NZ)
3) does the draft status have an appeals process - was it included in error. Likelihood that an error is way too small - this is critical information they are producing
removal of reimbursement is major. The only good news is they have a huge amount of cash to burn and if the SP was to crash it may provide a good buying opportunity for the brave
